1 / 11

Aarkstore - Antibody Drug Conjugate Insight

Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. Browse full report @ http://bit.ly/19p5nBl

JustinSterling
Download Presentation

Aarkstore - Antibody Drug Conjugate Insight

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals and Healthcare Aarkstore - Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015

  2. Summary Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region. Browse Complete Report – http://www.aarkstore.com/pharmaceuticals-healthcare/106496/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape

  3. Report Facts Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Billions of dollars are spent on the chemotherapy treatments annually. Different Biotechnology companies and Pharma Companies are collaborating in all area of ADCs like linker technology, antibody production and conjugation process. Seattle Genetics’s Brentuximab vedotin and Roche’s trastuzumab emtansine are the only ADCs approved which have together made USD 523 millions sales in 2013. There are total 264 ADCs in pipeline with 253 ADCS are developing only for Oncology indications. Pipeline is very rich with four potential drugs in Phase III stage out of which Kadcyla and Adcetris are undergoing clinical studies for different conditions.

  4. Scope  • A snapshot of the global Antibody-Drug Conjugate market scenario, market trends & drivers, manacles of Antibody-Drug Conjugate. • A review of the marketed Antibody-Drug Conjugate products and marketing status • Coverage of global antibody-drug conjugate therapies under development across the globe covering territories • Competitive landscape of investigational products for key players and key therapy areas. • The Antibody-Drug Conjugate report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information

  5. Reasons to buy • Complete Market and Pipeline intelligence and complete understanding over therapeutics development for Antibody-Drug Conjugate • Devise corrective measures for pipeline projects by understanding Therapy area specific therapies • Developing strategic initiatives to support your Antibody-Drug Conjugate development activities. • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

  6. Table of Content • Introduction 13 • Executive Summary 13 • Scope of the Report 14 • Antibody-Drug Conjugate Introduction 15 • Historical Perspective of Antibody-Drug Conjugate 15 • Design of Antibody-Drug Conjugate 17 • Different components of Antibody-Drug Conjugate 17 • Immunocongugate–A distinct class of therapeutics in Oncology 20 • Advantages of ADC over Traditional Therapies 21 • Important Hurdles Faced in Development and Commercialization of ADC 22

  7. List of Tables Table 1: Marketed and Pipeline Antibody-Drug Conjugates, 2015 Table 2: Antibody-Drug Conjugate in Pipeline by Phase, 2015 Table 3: Therapeutic Areas under Research for Antibody-Drug Conjugate Products, 2015 Table 4: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015 Table 5: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015 Table 6: Number of Technologies with Companies for Antibody-Drug Conjugate Products Development, 2015 Table 7: Number of Companies Technology for Antibody-Drug Conjugates Development, 2015 Table 8: Number of Companies with Monoclonal Antibodies for Antibody-Drug Conjugates Development, 2015

  8. List of Figures Figure 1: Marketed and Pipeline Antibody-Drug Conjugates, 2015 Figure 2: Phase III Antibody-Drug Conjugates and Trials, 2015 Figure 3: Comparison Graph for Discovery and Pre-clinical Antibody-Drug Conjugates, 2015 Figure 4: Antibody-Drug Conjugate in Pipeline by Phase, 2015 Figure 5: Therapeutic Areas under Research for Antibody-Drug Conjugate Products, 2015 Figure 6: Total Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015 Figure 7: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015 Figure 8: Number of Technologies with Companies for Antibody-Drug Conjugate Products Development, 2015 Figure 9: Number of Companies with Technology for Antibody-Drug Conjugates Development, 2015

  9. Related reports: • HER-2 Positive Breast Cancer Market in the US 2015-2019 • Global Small Cell Lung Cancer Therapeutics Market 2015-2019 • Global Osteoarthritis Market 2015-2019 • Global Laboratory Information Management System (LIMS) Market 2015-2019 • Global In-vitro Fertilization (IVF) Devices Market 2015-2019 • Global Acute Coronary Syndrome (ACS) Market 2015-2019 • Global Automated External Defibrillator Market 2015-2019 • Global Gaucher Disease Market 2015-2019 • Global In-vitro Fertilization (IVF) Devices Market 2015-2019 • Global Laboratory Information Management System (LIMS) Market 2015-2019

  10. Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015 Published: Mar 2015 | 342 Pages Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. Price

  11. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related